{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T14:06:20Z","timestamp":1794405980673,"version":"4.9.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T00:00:00Z","timestamp":1745625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T00:00:00Z","timestamp":1745625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s10067-025-07451-7","type":"journal-article","created":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T03:54:35Z","timestamp":1745639675000},"page":"637-650","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["CAR-T cell therapy in rheumatic diseases: a review article"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-2000-7924","authenticated-orcid":false,"given":"Harshwardhan","family":"Patil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7241-3380","authenticated-orcid":false,"given":"Rajath K.","family":"Bharadwaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1531-2484","authenticated-orcid":false,"given":"Nilanjana","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7192-7271","authenticated-orcid":false,"given":"Ramaswamy","family":"Subramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8134-8540","authenticated-orcid":false,"given":"Shiva","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7421-2418","authenticated-orcid":false,"given":"Mahabaleshwar","family":"Mamadapur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,26]]},"reference":[{"key":"7451_CR1","doi-asserted-by":"publisher","first-page":"e002907","DOI":"10.1136\/rmdopen-2022-002907","volume":"9","author":"U Blache","year":"2023","unstructured":"Blache U, Tretbar S, Koehl U et al (2023) CAR T cells for treating autoimmune diseases. RMD Open 9:e002907. https:\/\/doi.org\/10.1136\/rmdopen-2022-002907","journal-title":"RMD Open"},{"key":"7451_CR2","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/s0889-857x(05)70327-6","volume":"23","author":"BH Segal","year":"1997","unstructured":"Segal BH, Sneller MC (1997) Infectious complications of immunosuppressive therapy in patients with rheumatic diseases. Rheum Dis Clin North Am 23:219\u2013237. https:\/\/doi.org\/10.1016\/s0889-857x(05)70327-6","journal-title":"Rheum Dis Clin North Am"},{"key":"7451_CR3","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/s41584-024-01169-7","volume":"20","author":"V Konzett","year":"2024","unstructured":"Konzett V, Aletaha D (2024) Management strategies in rheumatoid arthritis. Nat Rev Rheumatol 20:760\u2013769. https:\/\/doi.org\/10.1038\/s41584-024-01169-7","journal-title":"Nat Rev Rheumatol"},{"key":"7451_CR4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3892\/mmr.2024.13171","volume":"29","author":"D Sun","year":"2024","unstructured":"Sun D, Shi X, Li S et al (2024) CAR-T cell therapy: a breakthrough in traditional cancer treatment strategies (Review). Mol Med Rep 29:47. https:\/\/doi.org\/10.3892\/mmr.2024.13171","journal-title":"Mol Med Rep"},{"key":"7451_CR5","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM (2021) CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J 11:69. https:\/\/doi.org\/10.1038\/s41408-021-00459-7","journal-title":"Blood Cancer J"},{"key":"7451_CR6","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","volume":"32","author":"M-L Schubert","year":"2021","unstructured":"Schubert M-L, Schmitt M, Wang L et al (2021) Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Ann Oncol 32:34\u201348. https:\/\/doi.org\/10.1016\/j.annonc.2020.10.478","journal-title":"Ann Oncol"},{"key":"7451_CR7","doi-asserted-by":"publisher","first-page":"238","DOI":"10.3390\/biom11020238","volume":"11","author":"C Bao","year":"2021","unstructured":"Bao C, Gao Q, Li L-L et al (2021) The application of nanobody in CAR-T therapy. Biomolecules 11:238. https:\/\/doi.org\/10.3390\/biom11020238","journal-title":"Biomolecules"},{"key":"7451_CR8","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","volume":"19","author":"S Depil","year":"2020","unstructured":"Depil S, Duchateau P, Grupp SA et al (2020) \u2018Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov 19:185\u2013199. https:\/\/doi.org\/10.1038\/s41573-019-0051-2","journal-title":"Nat Rev Drug Discov"},{"key":"7451_CR9","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1038\/s41423-020-0472-1","volume":"18","author":"X Jin","year":"2021","unstructured":"Jin X, Xu Q, Pu C et al (2021) Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus. Cell Mol Immunol 18:1896\u20131903. https:\/\/doi.org\/10.1038\/s41423-020-0472-1","journal-title":"Cell Mol Immunol"},{"key":"7451_CR10","doi-asserted-by":"publisher","first-page":"100826","DOI":"10.1016\/j.currproblcancer.2021.100826","volume":"46","author":"N Denlinger","year":"2022","unstructured":"Denlinger N, Bond D, Jaglowski S (2022) CAR T-cell therapy for B-cell lymphoma. Curr Probl Cancer 46:100826. https:\/\/doi.org\/10.1016\/j.currproblcancer.2021.100826","journal-title":"Curr Probl Cancer"},{"key":"7451_CR11","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41584-024-01139-z","volume":"20","author":"G Schett","year":"2024","unstructured":"Schett G, M\u00fcller F, Taubmann J et al (2024) Advancements and challenges in CAR T cell therapy in autoimmune diseases. Nat Rev Rheumatol 20:531\u2013544. https:\/\/doi.org\/10.1038\/s41584-024-01139-z","journal-title":"Nat Rev Rheumatol"},{"key":"7451_CR12","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","volume":"28","author":"A Mackensen","year":"2022","unstructured":"Mackensen A, M\u00fcller F, Mougiakakos D et al (2022) Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med 28:2124\u20132132. https:\/\/doi.org\/10.1038\/s41591-022-02017-5","journal-title":"Nat Med"},{"key":"7451_CR13","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.4049\/jimmunol.0902592","volume":"184","author":"KM Nickerson","year":"2010","unstructured":"Nickerson KM, Christensen SR, Shupe J et al (2010) TLR9 regulates TLR7- and MyD88-dependent autoantibody production and disease in a murine model of lupus. J Immunol 184:1840\u20131848. https:\/\/doi.org\/10.4049\/jimmunol.0902592","journal-title":"J Immunol"},{"key":"7451_CR14","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1002\/art.30613","volume":"63","author":"R Furie","year":"2011","unstructured":"Furie R, Petri M, Zamani O et al (2011) A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 63:3918\u20133930. https:\/\/doi.org\/10.1002\/art.30613","journal-title":"Arthritis Rheum"},{"key":"7451_CR15","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41584-019-0214-x","volume":"15","author":"J McHugh","year":"2019","unstructured":"McHugh J (2019) CAR T cells drive out B cells in SLE. Nat Rev Rheumatol 15:249\u2013249. https:\/\/doi.org\/10.1038\/s41584-019-0214-x","journal-title":"Nat Rev Rheumatol"},{"key":"7451_CR16","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F M\u00fcller","year":"2024","unstructured":"M\u00fcller F, Taubmann J, Bucci L et al (2024) CD19 CAR T-Cell therapy in autoimmune disease - a case series with follow-up. N Engl J Med 390:687\u2013700. https:\/\/doi.org\/10.1056\/NEJMoa2308917","journal-title":"N Engl J Med"},{"key":"7451_CR17","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1002\/acr2.11614","volume":"5","author":"A Boulougoura","year":"2023","unstructured":"Boulougoura A, Gendelman H, Surmachevska N, Kyttaris VC (2023) Journal Club: anti-CD19 chimeric antigen receptor T cell therapy for refractory systemic lupus erythematosus. ACR Open Rheumatol 5:624\u2013628. https:\/\/doi.org\/10.1002\/acr2.11614","journal-title":"ACR Open Rheumatol"},{"key":"7451_CR18","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMc2107725","volume":"385","author":"D Mougiakakos","year":"2021","unstructured":"Mougiakakos D, Kr\u00f6nke G, V\u00f6lkl S et al (2021) CD19-targeted CAR T cells in refractory systemic lupus erythematosus. N Engl J Med 385:567\u2013569. https:\/\/doi.org\/10.1056\/NEJMc2107725","journal-title":"N Engl J Med"},{"key":"7451_CR19","unstructured":"Chauhan K, Jandu JS, Brent LH et al (2023) Rheumatoid arthritis. In: StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL). Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK441999\/. Accessed 2 Jan 2025"},{"key":"7451_CR20","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41413-018-0016-9","volume":"6","author":"Q Guo","year":"2018","unstructured":"Guo Q, Wang Y, Xu D et al (2018) Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res 6:15. https:\/\/doi.org\/10.1038\/s41413-018-0016-9","journal-title":"Bone Res"},{"key":"7451_CR21","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.36922\/gpd.2851","volume":"3","author":"X Yu","year":"2024","unstructured":"Yu X, Shang H, Shen X, Zhang J et al (2024) Application and research progress of CAR-T cell therapy in autoimmune diseases. Gene Protein Dis 3:2851. https:\/\/doi.org\/10.36922\/gpd.2851","journal-title":"Gene Protein Dis"},{"key":"7451_CR22","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1097\/BOR.0000000000000540","volume":"30","author":"I Pinal-Fernandez","year":"2018","unstructured":"Pinal-Fernandez I, Mammen AL (2018) Dermatomyositis etiopathogenesis: a rebel soldier in the muscle. Curr Opin Rheumatol 30:623\u2013629. https:\/\/doi.org\/10.1097\/BOR.0000000000000540","journal-title":"Curr Opin Rheumatol"},{"key":"7451_CR23","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/s41584-023-01033-0","volume":"19","author":"T Khoo","year":"2023","unstructured":"Khoo T, Lilleker JB, Thong BY-H et al (2023) Epidemiology of the idiopathic inflammatory myopathies. Nat Rev Rheumatol 19:695\u2013712. https:\/\/doi.org\/10.1038\/s41584-023-01033-0","journal-title":"Nat Rev Rheumatol"},{"key":"7451_CR24","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/ana.20464","volume":"57","author":"SA Greenberg","year":"2005","unstructured":"Greenberg SA, Pinkus JL, Pinkus GS et al (2005) Interferon-\u03b1\/\u03b2\u2013mediated innate immune mechanisms in dermatomyositis. Ann Neurol 57:664\u2013678. https:\/\/doi.org\/10.1002\/ana.20464","journal-title":"Ann Neurol"},{"key":"7451_CR25","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1212\/WNL.59.8.1170","volume":"59","author":"SA Greenberg","year":"2002","unstructured":"Greenberg SA, Sanoudou D, Haslett JN et al (2002) Molecular profiles of inflammatory myopathies. Neurology 59:1170\u20131182. https:\/\/doi.org\/10.1212\/WNL.59.8.1170","journal-title":"Neurology"},{"key":"7451_CR26","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1016\/j.jid.2017.05.035","volume":"137","author":"ES Robinson","year":"2017","unstructured":"Robinson ES, Alves P, Bashir MM et al (2017) Cannabinoid reduces inflammatory cytokines, tumor necrosis factor-\u03b1, and type I interferons in dermatomyositis in vitro. J Invest Dermatol 137:2445\u20132447. https:\/\/doi.org\/10.1016\/j.jid.2017.05.035","journal-title":"J Invest Dermatol"},{"issue":"2013","key":"7451_CR27","doi-asserted-by":"publisher","first-page":"835948","DOI":"10.1155\/2013\/835948","volume":"23","author":"SA Jimenez","year":"2013","unstructured":"Jimenez SA (2013) Role of endothelial to mesenchymal transition in the pathogenesis of the vascular alterations in systemic sclerosis. ISRN Rheumatol 23(2013):835948. https:\/\/doi.org\/10.1155\/2013\/835948","journal-title":"ISRN Rheumatol"},{"key":"7451_CR28","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1093\/rheumatology\/keh671","volume":"44","author":"FA Wollheim","year":"2005","unstructured":"Wollheim FA (2005) Classification of systemic sclerosis. Visions and reality**Dedicated to the memory of E. Carwile LeRoy, 1933\u20132002. Rheumatology 44:1212\u20131216. https:\/\/doi.org\/10.1093\/rheumatology\/keh671","journal-title":"Rheumatology"},{"key":"7451_CR29","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1136\/annrheumdis-2018-213455","volume":"78","author":"W Wu","year":"2019","unstructured":"Wu W, Jordan S, Graf N et al (2019) Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort. Ann Rheum Dis 78:648\u2013656. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213455","journal-title":"Ann Rheum Dis"},{"key":"7451_CR30","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1097\/BOR.0000000000000898","volume":"34","author":"P-S Tsou","year":"2022","unstructured":"Tsou P-S, Shi B, Varga J (2022) Role of cellular senescence in the pathogenesis of systemic sclerosis. Curr Opin Rheumatol 34:343\u2013350. https:\/\/doi.org\/10.1097\/BOR.0000000000000898","journal-title":"Curr Opin Rheumatol"},{"key":"7451_CR31","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1136\/ard-2023-223952","volume":"82","author":"C Bergmann","year":"2023","unstructured":"Bergmann C, M\u00fcller F, Distler JHW et al (2023) Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells. Ann Rheum Dis 82:1117\u20131120. https:\/\/doi.org\/10.1136\/ard-2023-223952","journal-title":"Ann Rheum Dis"},{"key":"7451_CR32","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.berh.2009.12.002","volume":"24","author":"D Khanna","year":"2010","unstructured":"Khanna D, Denton CP (2010) Evidence-based management of rapidly progressing systemic sclerosis. Best Pract Res Clin Rheumatol 24:387\u2013400. https:\/\/doi.org\/10.1016\/j.berh.2009.12.002","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"7451_CR33","doi-asserted-by":"publisher","first-page":"e489","DOI":"10.1016\/S2665-9913(21)00107-7","volume":"3","author":"S Ebata","year":"2021","unstructured":"Ebata S, Yoshizaki A, Oba K et al (2021) Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial. Lancet Rheumatol 3:e489\u2013e497. https:\/\/doi.org\/10.1016\/S2665-9913(21)00107-7","journal-title":"Lancet Rheumatol"},{"key":"7451_CR34","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41586-020-2403-9","volume":"583","author":"C Amor","year":"2020","unstructured":"Amor C, Feucht J, Leibold J et al (2020) Senolytic CAR T cells reverse senescence-associated pathologies. Nature 583:127\u2013132. https:\/\/doi.org\/10.1038\/s41586-020-2403-9","journal-title":"Nature"},{"key":"7451_CR35","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1097\/01.bor.0000179945.73518.28","volume":"17","author":"M Fujimoto","year":"2005","unstructured":"Fujimoto M, Sato S (2005) B lymphocytes and systemic sclerosis. Curr Opin Rheumatol 17:746\u2013751. https:\/\/doi.org\/10.1097\/01.bor.0000179945.73518.28","journal-title":"Curr Opin Rheumatol"},{"key":"7451_CR36","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1002\/art.41812","volume":"73","author":"C Orvain","year":"2021","unstructured":"Orvain C, Boulch M, Bousso P et al (2021) Is there a place for chimeric antigen receptor\u2013T cells in the treatment of chronic autoimmune rheumatic diseases? Arthritis Rheumatol 73:1954\u20131965. https:\/\/doi.org\/10.1002\/art.41812","journal-title":"Arthritis Rheumatol"},{"key":"7451_CR37","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1097\/MOT.0000000000000566","volume":"23","author":"A Sicard","year":"2018","unstructured":"Sicard A, Boardman DA, Levings MK (2018) Taking regulatory T-cell therapy one step further. Curr Opin Organ Transplant 23:509\u2013515. https:\/\/doi.org\/10.1097\/MOT.0000000000000566","journal-title":"Curr Opin Organ Transplant"},{"key":"7451_CR38","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3389\/fimmu.2019.00046","volume":"10","author":"RE Hoeppli","year":"2019","unstructured":"Hoeppli RE, Pesenacker AM (2019) Targeting Tregs in juvenile idiopathic arthritis and juvenile dermatomyositis\u2014insights from other diseases. Front Immunol 10:46. https:\/\/doi.org\/10.3389\/fimmu.2019.00046","journal-title":"Front Immunol"},{"key":"7451_CR39","doi-asserted-by":"publisher","first-page":"102211","DOI":"10.1016\/j.coph.2022.102211","volume":"64","author":"H Bukiri","year":"2022","unstructured":"Bukiri H, Volkmann ER (2022) Current advances in the treatment of systemic sclerosis. Curr Opin Pharmacol 64:102211. https:\/\/doi.org\/10.1016\/j.coph.2022.102211","journal-title":"Curr Opin Pharmacol"},{"key":"7451_CR40","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","volume":"380","author":"O Distler","year":"2019","unstructured":"Distler O, Highland KB, Gahlemann M et al (2019) Nintedanib for systemic sclerosis\u2013associated interstitial lung disease. N Engl J Med 380:2518\u20132528. https:\/\/doi.org\/10.1056\/NEJMoa1903076","journal-title":"N Engl J Med"},{"key":"7451_CR41","doi-asserted-by":"publisher","first-page":"3897","DOI":"10.1007\/s10067-021-05698-4","volume":"40","author":"M Moradzadeh","year":"2021","unstructured":"Moradzadeh M, Aghaei M, Mehrbakhsh Z et al (2021) Efficacy and safety of rituximab therapy in patients with systemic sclerosis disease (SSc): systematic review and meta-analysis. Clin Rheumatol 40:3897\u20133918. https:\/\/doi.org\/10.1007\/s10067-021-05698-4","journal-title":"Clin Rheumatol"},{"key":"7451_CR42","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1007\/s10067-021-05665-z","volume":"40","author":"K Melissaropoulos","year":"2021","unstructured":"Melissaropoulos K, Daoussis D (2021) B cells in systemic sclerosis: from pathophysiology to treatment. Clin Rheumatol 40:2621\u20132631. https:\/\/doi.org\/10.1007\/s10067-021-05665-z","journal-title":"Clin Rheumatol"},{"key":"7451_CR43","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.3389\/fimmu.2018.02356","volume":"9","author":"C Frantz","year":"2018","unstructured":"Frantz C, Auffray C, Avouac J, Allanore Y (2018) Regulatory T cells in systemic sclerosis. Front Immunol 9:2356. https:\/\/doi.org\/10.3389\/fimmu.2018.02356","journal-title":"Front Immunol"},{"key":"7451_CR44","doi-asserted-by":"publisher","first-page":"e5981","DOI":"10.1371\/journal.pone.0005981","volume":"4","author":"TRDJ Radstake","year":"2009","unstructured":"Radstake TRDJ, Van Bon L, Broen J et al (2009) Increased frequency and compromised function of T regulatory cells in systemic sclerosis (SSc) is related to a diminished CD69 and TGF\u03b2 expression. PLoS ONE 4:e5981. https:\/\/doi.org\/10.1371\/journal.pone.0005981","journal-title":"PLoS ONE"},{"key":"7451_CR45","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1136\/annrheumdis-2011-200709","volume":"71","author":"A Mathian","year":"2012","unstructured":"Mathian A, Parizot C, Dorgham K et al (2012) Activated and resting regulatory T cell exhaustion concurs with high levels of interleukin-22 expression in systemic sclerosis lesions. Ann Rheum Dis 71:1227\u20131234. https:\/\/doi.org\/10.1136\/annrheumdis-2011-200709","journal-title":"Ann Rheum Dis"},{"key":"7451_CR46","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.3389\/fimmu.2020.01973","volume":"11","author":"EL Siegler","year":"2020","unstructured":"Siegler EL, Kenderian SS (2020) Neurotoxicity and cytokine release syndrome after chimeric antigen receptor T cell therapy: insights into mechanisms and novel therapies. Front Immunol 11:1973. https:\/\/doi.org\/10.3389\/fimmu.2020.01973","journal-title":"Front Immunol"},{"key":"7451_CR47","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1093\/rheumatology\/kes090","volume":"51","author":"S O\u2019Reilly","year":"2012","unstructured":"O\u2019Reilly S, Hugle T, Van Laar JM (2012) T cells in systemic sclerosis: a reappraisal. Rheumatology 51:1540\u20131549. https:\/\/doi.org\/10.1093\/rheumatology\/kes090","journal-title":"Rheumatology"},{"key":"7451_CR48","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1684\/ecn.2013.0325","volume":"23","author":"NC Brembilla","year":"2012","unstructured":"Brembilla NC, Chizzolini C (2012) T cell abnormalities in systemic sclerosis with a focus on Th17 cells. Eur Cytokine Netw 23:128\u2013139. https:\/\/doi.org\/10.1684\/ecn.2013.0325","journal-title":"Eur Cytokine Netw"},{"key":"7451_CR49","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41586-019-1546-z","volume":"573","author":"H Aghajanian","year":"2019","unstructured":"Aghajanian H, Kimura T, Rurik JG et al (2019) Targeting cardiac fibrosis with engineered T cells. Nature 573:430\u2013433. https:\/\/doi.org\/10.1038\/s41586-019-1546-z","journal-title":"Nature"},{"key":"7451_CR50","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1016\/S2665-9913(24)00282-0","volume":"7","author":"J Auth","year":"2025","unstructured":"Auth J, M\u00fcller F, V\u00f6lkl S et al (2025) CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series. Lancet Rheumatol 7:e83\u2013e93. https:\/\/doi.org\/10.1016\/S2665-9913(24)00282-0","journal-title":"Lancet Rheumatol"},{"key":"7451_CR51","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.abm0594","volume":"375","author":"JG Rurik","year":"2022","unstructured":"Rurik JG, Tomb\u00e1cz I, Yadegari A et al (2022) CAR T cells produced in vivo to treat cardiac injury. Science 375:91\u201396. https:\/\/doi.org\/10.1126\/science.abm0594","journal-title":"Science"},{"issue":"6","key":"7451_CR52","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.autrev.2018.12.007","volume":"18","author":"X Wu","year":"2019","unstructured":"Wu X, Liu Y, Wei W, Liu ML (2019) Extracellular vesicles in autoimmune vasculitis - little dirts light the fire in blood vessels. Autoimmun Rev. 18(6):593\u2013606. https:\/\/doi.org\/10.1016\/j.autrev.2018.12.007","journal-title":"Autoimmun Rev."},{"key":"7451_CR53","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41572-020-0204-y","volume":"6","author":"AR Kitching","year":"2020","unstructured":"Kitching AR, Anders H-J, Basu N et al (2020) ANCA-associated vasculitis. Nat Rev Dis Primer 6:71. https:\/\/doi.org\/10.1038\/s41572-020-0204-y","journal-title":"Nat Rev Dis Primer"},{"key":"7451_CR54","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1136\/ard-2023-224875","volume":"83","author":"D Lodka","year":"2024","unstructured":"Lodka D, Zschummel M, Bunse M et al (2024) CD19-targeting CAR T cells protect from ANCA-induced acute kidney injury. Ann Rheum Dis 83:499\u2013507. https:\/\/doi.org\/10.1136\/ard-2023-224875","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"7451_CR55","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty RE, Southwood TR, Manners P et al (2004) International league of associations for rheumatology. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 31(2):390\u20132","journal-title":"J Rheumatol"},{"key":"7451_CR56","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","volume":"76","author":"IE Lundberg","year":"2017","unstructured":"Lundberg IE, Tj\u00e4rnlund A, Bottai M et al (2017) 2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis 76:1955\u20131964. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211468","journal-title":"Ann Rheum Dis"},{"key":"7451_CR57","doi-asserted-by":"publisher","first-page":"394","DOI":"10.55563\/clinexprheumatol\/56ilob","volume":"40","author":"LJ McCann","year":"2022","unstructured":"McCann LJ, Livermore P, Wilkinson MGL, Wedderburn LR (2022) Juvenile dermatomyositis Where are we now? Clin Exp Rheumatol 40:394\u2013403. https:\/\/doi.org\/10.55563\/clinexprheumatol\/56ilob","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"7451_CR58","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s12969-021-00629-8","volume":"19","author":"LN Zaripova","year":"2021","unstructured":"Zaripova LN, Midgley A, Christmas SE, Beresford MW, Baildam EM, Oldershaw RA (2021) Juvenile idiopathic arthritis: from aetiopathogenesis to therapeutic approaches. Pediatr Rheumatol Online J 19(1):135. https:\/\/doi.org\/10.1186\/s12969-021-00629-8","journal-title":"Pediatr Rheumatol Online J"},{"key":"7451_CR59","doi-asserted-by":"publisher","first-page":"1492552","DOI":"10.3389\/fimmu.2024.1492552","volume":"15","author":"J Liu","year":"2024","unstructured":"Liu J, Zhao Y, Zhao H (2024) Chimeric antigen receptor T-cell therapy in autoimmune diseases. Front Immunol 15:1492552. https:\/\/doi.org\/10.3389\/fimmu.2024.1492552","journal-title":"Front Immunol"},{"issue":"10416","key":"7451_CR60","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1016\/S0140-6736(23)01126-1","volume":"402","author":"G Schett","year":"2023","unstructured":"Schett G, Mackensen A, Mougiakakos D (2023) CAR T-cell therapy in autoimmune diseases. Lancet 402(10416):2034\u20132044. https:\/\/doi.org\/10.1016\/S0140-6736(23)01126-1","journal-title":"Lancet"},{"key":"7451_CR61","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","volume":"8","author":"BD Santomasso","year":"2018","unstructured":"Santomasso BD, Park JH, Salloum D et al (2018) Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov 8:958\u2013971. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-1319","journal-title":"Cancer Discov"},{"issue":"4","key":"7451_CR62","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL et al (2019) ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 25(4):625\u2013638. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.758","journal-title":"Biol Blood Marrow Transplant"},{"key":"7451_CR63","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s00296-024-05772-5","volume":"45","author":"L Kattamuri","year":"2025","unstructured":"Kattamuri L, Mohan Lal B, Vojjala N et al (2025) Safety and efficacy of CAR-T cell therapy in patients with autoimmune diseases: a systematic review. Rheumatol Int 45:18. https:\/\/doi.org\/10.1007\/s00296-024-05772-5","journal-title":"Rheumatol Int"},{"issue":"7","key":"7451_CR64","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1001\/jamaoncol.2018.0977","volume":"4","author":"I Hernandez","year":"2018","unstructured":"Hernandez I, Prasad V, Gellad WF (2018) Total costs of chimeric antigen receptor T-cell immunotherapy. JAMA Oncol 4(7):994\u2013996. https:\/\/doi.org\/10.1001\/jamaoncol.2018.0977","journal-title":"JAMA Oncol"},{"issue":"1","key":"7451_CR65","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","volume":"23","author":"CA Jacobson","year":"2022","unstructured":"Jacobson CA, Chavez JC, Sehgal AR, William BM, Munoz J, Salles G, Munshi PN, Casulo C, Maloney DG, de Vos S, Reshef R, Leslie LA, Yakoub-Agha I, Oluwole OO, Fung HCH, Rosenblatt J, Rossi JM, Goyal L, Plaks V, Yang Y, Vezan R, Avanzi MP, Neelapu SS (2022) Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol 23(1):91\u2013103. https:\/\/doi.org\/10.1016\/S1470-2045(21)00591-X","journal-title":"Lancet Oncol"},{"issue":"1","key":"7451_CR66","doi-asserted-by":"publisher","first-page":"53","DOI":"10.5414\/CN111197","volume":"103","author":"Z Tang","year":"2025","unstructured":"Tang Z, Huang Y, Lin Y et al (2025) Efficacy and safety of rituximab in patients with lupus nephritis: a systematic review and meta-analysis. Clin Nephrol 103(1):53\u201362. https:\/\/doi.org\/10.5414\/CN111197","journal-title":"Clin Nephrol"},{"issue":"1","key":"7451_CR67","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/art.27233","volume":"62","author":"JT Merrill","year":"2010","unstructured":"Merrill JT, Neuwelt CM, Wallace DJ et al (2010) Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 62(1):222\u2013233. https:\/\/doi.org\/10.1002\/art.27233","journal-title":"Arthritis Rheum"},{"key":"7451_CR68","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/art.37754","volume":"65","author":"CV Oddis","year":"2013","unstructured":"Oddis CV, Reed AM, Aggarwal R et al (2013) Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 65:314\u2013324. https:\/\/doi.org\/10.1002\/art.37754","journal-title":"Arthritis Rheum"},{"key":"7451_CR69","doi-asserted-by":"publisher","unstructured":"Lungova K, Putman M (2024) Barriers to CAR T-cell therapy in rheumatology. Lancet Rheumatol S2665-9913(24)00240-6. https:\/\/doi.org\/10.1016\/S2665-9913(24)00240-6","DOI":"10.1016\/S2665-9913(24)00240-6"},{"key":"7451_CR70","unstructured":"ClinicalTrials.gov [Internet]. National Library of Medicine (US), Bethesda (MD). Available from: \nhttps:\/\/clinicaltrials.gov\/. Accessed 7 Feb 2025"},{"issue":"10","key":"7451_CR71","doi-asserted-by":"publisher","first-page":"895065","DOI":"10.3389\/fped.2022.895065","volume":"18","author":"F Vittoria","year":"2022","unstructured":"Vittoria F, Ceconi V, Fantina L, Barbi E, Carbone M (2022) Effectiveness and safety of a one-yearly elongation approach of growing rods in the treatment of early-onset scoliosis: a case series of 40 patients with definitive fusion. Front Pediatr 18(10):895065. https:\/\/doi.org\/10.3389\/fped.2022.895065","journal-title":"Front Pediatr"},{"issue":"1","key":"7451_CR72","doi-asserted-by":"publisher","first-page":"6957","DOI":"10.1038\/s41598-023-32692-4","volume":"13","author":"G Xi","year":"2023","unstructured":"Xi G, Cheng R, Liang L et al (2023) High expression of RNF31 is associated with tumor immune cell infiltration and leads to poor prognosis in liver hepatocellular carcinoma. Sci Rep 13(1):6957. https:\/\/doi.org\/10.1038\/s41598-023-32692-4","journal-title":"Sci Rep"},{"key":"7451_CR73","doi-asserted-by":"publisher","first-page":"895065","DOI":"10.3389\/fped.2022.895065","volume":"10","author":"F Vittoria","year":"2022","unstructured":"Vittoria F, Ceconi V, Fantina L et al (2022) Effectiveness and safety of a one-yearly elongation approach of growing rods in the treatment of early-onset scoliosis: a case series of 40 patients with definitive fusion. Front Pediatr 10:895065. https:\/\/doi.org\/10.3389\/fped.2022.895065","journal-title":"Front Pediatr"},{"key":"7451_CR74","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1126\/science.aaf6756","volume":"353","author":"CT Ellebrecht","year":"2016","unstructured":"Ellebrecht CT, Bhoj VG, Nace A et al (2016) Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. Science 353:179\u2013184. https:\/\/doi.org\/10.1126\/science.aaf6756","journal-title":"Science"},{"key":"7451_CR75","doi-asserted-by":"publisher","first-page":"603237","DOI":"10.3389\/fimmu.2020.603237","volume":"11","author":"M SadeqiNezhad","year":"2020","unstructured":"SadeqiNezhad M, Seifalian A, Bagheri N et al (2020) Chimeric antigen receptor based therapy as a potential approach in autoimmune diseases: how close are we to the treatment? Front Immunol 11:603237. https:\/\/doi.org\/10.3389\/fimmu.2020.603237","journal-title":"Front Immunol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07451-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-025-07451-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07451-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T09:01:50Z","timestamp":1769763710000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-025-07451-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,26]]},"references-count":75,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["7451"],"URL":"https:\/\/doi.org\/10.1007\/s10067-025-07451-7","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,26]]},"assertion":[{"value":"6 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}